Information Provided By:
Fly News Breaks for August 28, 2019
VRTX
Aug 28, 2019 | 11:44 EDT
The FDA Adverse Events Reporting System Public Dashboard citing 30 deaths with Symdeko caused volatility today in shares of Vertex Pharmaceuticals, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. After accessing the website, the analyst says none of the 30 deaths specifically indicate Symdeko, "but rather appear to be due to underlying cystic fibrosis disease." As such, the FAERS report does not signify a unique problem with Symdeko or Vertex's TripleRx combination, which is under review at the FDA, contends Tenthoff. The "timing of this short rumor to be suspicious during a quiet, end of summer week," he adds. The analyst continues to forecast Vertex's total cystic fibrosis sales at $3.7B this year, growing to $5B in 2020 with the TripleRx launch. He reiterates an Overweight rating on the stock with a $230 price target. Vertex in late morning trading is up 1%, or $1.84, to $180.09.
News For VRTX From the Last 2 Days
There are no results for your query VRTX